arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Program ANR2021

Monday 25 Jan

25 January 2021

Time zone CEST

16:00

Opening

Frank Speleman, Ghent, Belgium and Rogier Versteeg, Amsterdam, the Netherlands

16.05 - 17.05 Major Symposium 1: Progress in treatment and challenges for preclinical studies

Moderator: Angelika Eggert, Berlin, Germany and & Godfrey Chan, China

16:05

Introduction to symposium

Angelika Eggert, Berlin, Germany

16:15

Introduction of new HR-NBL2-SIOPEN trial

Dominique Valteau-Couanet, Villejuif, France

16:25

Introduction of new COG HR concept

Rochelle Bagatelle, Philadelphia, US

16:35

Current international relapse concepts/early clinical trials

Lucas Moreno, Barcelona, Spain

16:45

Low and intermediate risk neuroblastoma

Barbara Hero, Koln, Germany

16:55

MS1.1 Surviving High-Risk Neuroblastoma: A Preliminary Descriptive Report from Project LEAHRN (Late Effects After High-Risk Neuroblastoma)

Lisa Diller, Boston, USA

17:05

Break

17.10- 18.25 Major Symposium 2: Neuroblastoma as a developmental disorder

Moderator: Olivier Delattre, Paris, France and & Herman Rohrer, Germany

17:10

Introduction to symposium

Olivier Delattre, Paris, France

17:15

Introduction on normal sympatho-adrenergic lineage development

Igor Adameyko, Stockholm, Sweden

17:25

MS2.1 Developmental and oncogenic programs in neuroblastomas dissected by single-cell analysis

Selina Jansky, Heidelberg, Germany

17:40

MS2.2 Single-cell RNA sequencing of human neuroblastoma reveals Schwann cell precursors as putative cancer stem cells

Thale Kristin Olsen, Stockholm, Sweden

17:55

MS2.3 Dissecting neuroblastoma tumor heterogeneity and cell plasticity by single cell RNAseq

Cecile Thirant, Paris, France

18:10

MS2.4 Drug resistance and phenotype of MES- and ADRN-type neuroblastoma cells faithfully reflect consecutive stages of normal adrenergic lineage development

Johan Van Nes, Amsterdam, the Netherlands

18:25

Break

18.30 – 19.30 Parallel sessions

PA1: Treatment relapse Neuroblastoma

18:30

PA1.1 Relapsed/refractory pediatric neuroblastoma: excellent tolerability and sustained responses with temozolomide-based regimens

Lucy Métayer, Villejuif, France

18:45

PA1.2 Risk classification for patients with first recurrence of stage 4 neuroblastoma

Frank Berthold, Cologne, Germany

19:00

PA1.3 Randomized Phase II Trial of MIBG vs. MIBG/Vincristine/Irinotecan vs. MIBG/Vorinostat for Patients with Relapsed/Refractory Neuroblastoma: A Report from the New Approaches to Neuroblastoma Therapy

Steven DuBois, Boston, USA

19:15

PA1.4 Long Term Survival for Patients with Central Nervous System Metastases Following Treatment with Intraventricular Radiolabeled Omburtamab: Results of Trial 03-133

Kim Kramer, New York, USA

PA2: Omics, new concepts

18:30

PA2.1 Contribution of TWIST1 in the aggressiveness of neuroblastoma by modulation of the tumor-stroma crosstalk

Maria-Vittoria Sepporta, Lausanne, Switzerland

18:45

PA2.2 Targeting Fatty Acid Transport in MYCN-amplified Neuroblastoma

Eveline Barbieri, Houston, USA

19:00

PA2.3 MYCN regulates metabolism through vesicular transfer of glycolytic kinases

Arturo Sala, London, UK

19:15

PA2.4 Cellular and gene signatures of tumor-infiltrating dendritic cells and natural killer cells predict favorable clinical outcome of neuroblastoma

Ombretta Melaiu, Rome, Italy

PA3: Neuroblastoma as development disorder

18:30

PA3.1 Single cell transcriptome analysis decodes development trajectory of neural crest cells

Ran Yang, Shanghai, China

18:45

PA3.2 “A tale of two diseases”: a single-cell approach to neuroblastoma identifies two diseases entities, distinct for developmental origin, site of onset and genomic alteration profile

Alessandro Quattrone, Trento, Italy

19:00

PA3.3 ASCL1 activation by dephosphorylation can direct a genome-wide re-engagement of a latent differentiation programme in neuroblastoma

Lydia Parkinson, Cambridge, UK

19:15

PA3.4 The development of a human embryonic stem cell derived differentiation model to study normal and neuroblastoma development

Stéphane Van Haver, Ghent, Belgium

PA4: Clinical – Neuroblastoma frontline therapy

18:30

PA4.1 Natural history of ganglioneuroma (GN) and intermixed ganglioneuroblastoma (iGNB): An International Neuroblastoma Risk Group (INRG) project

Paola Angelini, Sutton, UK

18:45

PA4.2 Long-term health status of high-risk neuroblastoma survivors treated with high-dose chemotherapy and hematopoietic stem cell transplantation

Sandrine Haghiri, Villejuif, France

19:00

PA4.3 Neuroblastoma Patient-Derived Cell Lines and Xenografts in the COG/ALSF Childhood Cancer Repository

Kristyn McCoy, Lubbock, USA

19:15

PA4.4 The incidence of neuroblastoma cases before and after screening in Japan

Tomoko Iehara, Kyoto, Japan

19:30

End of day 1

Tuesday 26 Jan

26 January 2021

Time zone CEST

16.00-17.05 Major Symposium 3: A deep look into neuroblastoma

Moderators: Gudrun Schleiermacher, Paris, France and Susanne Schlisio, Solna, Sweden

16:00

Introduction to symposium

Gudrun Schleiermacher, Paris, France

16:05

MS3.1 Clonal heterogeneity before treatment underlies spatial and temporal evolution in neuroblastoma

Gunes Gundem, New York, USA

16:20

MS3.2 Molecular diagnostics and targeted therapy of neuroblastoma in light of intratumour heterogeneity

Karin Schmelz, Berlin, Germany

16:35

MS3.3 Single cell DNA sequencing and sequential circulating tumor DNA analysis highlight intratumor genetic heterogeneity and clonal evolution under targeted therapies in neuroblastoma

Angela Bellini, Paris, France

16:50

MS3.4 Single-cell RNA-sequencing of peripheral neuroblastic tumors identifies an aggressive transitional cell state at the junction of an adrenergic-mesenchymal transdifferentiation trajectory

Daniel Carter, Randwick, Australia

17:05

Break

17.10-18.15 Major Symposium 4: Neuroblastoma tumour biology and genomics: from bench to the clinic

Moderators: John Maris, Philadelphia, USA and Matthias Fischer, Cologne, Germany

17:10

Introduction to symposium

John Maris, Philadelphia, USA and Matthias Fischer, Cologne, Germany

17:15

MS4.1 The BRIP1 17q dependency gene in neuroblastoma: from fork stability to translation

Suzanne Vanhauwaert, Ghent, Belgium

17:30

MS4.2 A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma

Amber Weiner, Philadelphia, USA

17:45

MS4.3 The evolution of MDM2 and MYCN amplifications in neuroblastoma

Caroline Rosswog, Cologne, Germany

18:00

MS4.4 The transcriptional co-repressor Runx1t1 is essential for N-myc-driven neuroblastoma tumorigenesis

Murray Norris, Kensington, Australia

18:15

Break

18.20-19.20 Parallel sessions

PA5: Heterogeneity in Neuroblastoma

18:20

PA5.1 Single cell RNA-sequencing analysis of tumor heterogeneity and dynamic adaptive transcriptome changes in a MYCN driven zebrafish model

Lisa Depestel, Ghent, Belgium

18:35

PA5.2 Cross-talk between Tumor Associated Macrophages (TAM) and Cancer Associated Fibroblasts (CAF) in Neuroblastoma (NB) Contributes to a Pro-tumorigenic Microenvironment (TME) that Promotes TAM

Kevin Louault, Los Angeles, USA

18:50

PA5.3 Self-renewing neuroblastoma cells of the bone marrow share a mesenchymal phenotype which is associated with poor outcome: an NCRI CCL CSG Neuroblastoma Group Study

Susan Burchill, Leeds, UK

19:05

PA5.4 The landscape and evolution of somatic mutations captured in the NEPENTHE precision medicine clinical trial for relapsed high-risk neuroblastoma

Esther Berko, Philadelphia, USA

PA6:Targeted therapy

18:20

PA6.1 APR-246, which Restores p53 Function, is Highly Active against Alternative Lengthening of Telomere (ALT) Neuroblastoma Cell Lines and PDXs

Shawn Macha, Lubbock, USA

18:35

PA6.2 Integration of High-Throughput Drug Screening on Patient-Derived Organoids into the Princess Máxima Center iTHER Precision Medicine Program: The Future is Now!

Karin Langenberg, Utrecht, the Netherlands

18:50

PA6.3 Zero Childhood Cancer (ZERO): A comprehensive genomic, high-throughput drug screening and personalised xenograft modelling platform for high-risk cancer including relapsed/refractory high-risk neuroblastoma

Alvin Kamilii & Toby Trahair, Sydney, Australia

19:05

PA6.4 Synergistic antitumor effects of combining selective CDK7 and BRD4 inhibition in neuroblastoma

Malgorzata Krajewska, Boston, USA

PA7: Liquid biopsies

18:20

PA7.1 Combined blood and bone marrow cell-free DNA and disseminated tumor cell detection for sensitive response monitoring and early relapse detection in high-risk neuroblastoma patients

Sabine Taschner-Mandl, Vienna, Austria

18:35

PA7.2 Detection of actionable genetic alterations in cell-free DNA of neuroblastoma patients enrolled in the MAPPYACTS study

Gudrun Schleiermacher, Paris, France

18:50

PA7.3 Hypermethylated RASSF1A and tumor specific DNA breakpoints as circulating tumor markers for detection of minimal residual disease

Lieke Van Zogchel, Utrecht, the Netherlands

19:05

PA7.4 Combining genomics and ultra-sensitive bone marrow assessment for risk stratification in high-risk metastatic neuroblastoma: a HR-NBL1/SIOPEN study

Stefan Fiedler, Vienna, Austria

PA8: Immune therapy

18:20

PA8.1 Leveraging an immunocompetent, MYCN-driven, non-germline GEM model for neuroblastoma and CyTOF mass cytometry to investigate immunosuppressive mechanisms and response to immunotherapy

Marie Menard, San Francisco, USA

18:35

PA8.2 Analysis of immune checkpoints in patients with high-risk neuroblastoma treated with dinutuximab beta with and without IL-2

Holger Lode, Greifswald, Germany

18:50

PA8.3 The antibody-drug conjugate D3-GPC2-PBD is potently efficacious against diverse preclinical models of neuroblastoma and other cancers via engagement of a tumor-specific conformational GPC2 epitope

Kristopher Bosse, Philadelphia, USA

19:05

PA8.4 41BB or CD28 driven disialoganglioside (GD2)-specific CAR-T, but not T-cell engaging bispecific antibody, induces fatal neurotoxicity in mice

Brian Santich, New York, USA

19:20

End of day 2

Wednesday 27 Jan

27 January 2021

Time zone CEST

21.00-22.05 Major Symposium 5: Targeted therapy: ALK and other targets in personalized medicine

Moderators: Yael Mossé, Philadelphia, USA and Michelle Haber, Sydney, Australia

21:00

Introduction to symposium

Yael Mossé, Philadelphia, USA and Michelle Haber, Sydney, Australia

21:05

MS5.1 Phase 1 trial of Lorlatinib in patients with relapsed/refractory ALK-driven neuroblastoma

Kelly Goldsmith, Atlanta, USA and Esther Berko, Philadelphia, USA

21:20

MS5.2 Arginine depletion therapy enhances efficacy of chemotherapy in delaying tumour development and increasing survival in the Th-MYCN mouse model of neuroblastoma

Ruby Pandher, Sydney, Australia

21:35

MS5.3 Targeting transcription-replication conflicts in MYCN-driven neuroblastoma

Gabriele Buechel, Wurzburg, Germany

21:50

MS5.4 Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

Sally George, London, UK

22:05

Break

22.10-23.15 Major symposium 6 & Major symposium 7 (parallel)

22.10-23.15 Major symposium 6: Gene regulatory networks and epigenetics: from basic science towards novel therapeutic strategies

Moderators: Kimberly Stegmaier, Boston, USA and Rani George, Boston, USA

22:10

Introduction to symposium

Kimberly Stegmaier, Boston, USA and Rani George, Boston, USA

22:15

MS6.1 Extrachromosomal circular MYCN amplification: structure, regulation and genomic remodeling

Konstantin Helmsauer, Berlin, Germany

22:30

MS6.2 Three-dimensional analysis of MYCN function in neuroblastoma

Martin Eilers, Wurzburg, Germany

22:45

M6.3 Distinct roles of noradrenergic core regulatory circuitry transcription factors in neuroblastoma cell identity

Isabelle Janoueix-Lerosey, Paris, France

23:00

T.B.A.

Rani George, Boston, USA

22.10-23.15 Major Symposium 7: Immune therapy of neuroblastoma

Moderators: Julie Park, Seattle, USA and Holger Lode, Greifswald, Germany

22:10

Introduction to symposium

Julie Park, Seattle, USA and Holger Lode, Greifswald, Germany

22:15

MS7.1 Academic, Phase I/II Trial on T Cells Expressing a Third-Generation GD2 Chimeric Antigen Receptor and Inducible Caspase-9 Safety Switch for Treatment of Relapsed/Refractory High-Risk Neuroblastoma

Francesca Del Bufalo, Rome, Italy

22:30

MS7.2 Pharmacodynamic effects of IL-2 in the treatment with a long-term infusion of anti-GD2 antibody dinutuximab beta: Role in outcome and toxicity in high-risk relapsed/refractory neuroblastoma patients. Results of a randomized SIOPEN-study

Sascha Troschke-Meurer, Greifswald, Germany

22:45

MS7.3 The Composition, States and Dynamics of Microenvironmental Landscape of High-Risk Neuroblastoma Revealed by Single-Cell RNA Sequencing

Waleed Kholosy, Utrecht, the Netherlands

23:00

MS7.4 GD2 is a Macrophage Checkpoint Molecule and Combined GD2/CD47 Blockade Results in Synergistic Effects and Tumor Clearance in Xenograft Models of Neuroblastoma and Osteosarcoma

Robbie Majzner, Palo Alto, USA

23:15

Break

23.20-24.20 Parallel sessions

PA9: Genomics: new genes and concepts

23:20

PA9.1 The neuroblastoma dependency factor RRM2 is regulated during sympathoblast differentiation and represents a synergistic drug target for high-risk neuroblastoma

Carolina Nunes, Ghent, Belgium

23:35

PA9.2 The Yes-Associated Protein suppresses Harakiri to promote therapy resistance under tumor environmental stress in high-risk neuroblastoma

Jenny Shim, Atlanta, USA

23:50

PA9.3 Functional genomic screens identify the nuclear export factor NXT1 as a therapeutic target in MYCN-amplified neuroblastoma

Clare Malone, Boston, USA

00:05

PA9.4 Variations of DNA mismatch repair genes in hypermutated neuroblastoma

Audrey Petit, Paris, France

PA10: Targeted therapy: ALK resistance and new strategies

23:20

PA10.1 Adrenergic and Mesenchymal neuroblastoma cells have opposite resistance to ALK inhibitors and TRAIL, allowing dual therapy to impede resistance and relapse development

Ellen Westerhout, Amsterdam, the Netherlands

23:35

PA10.2 Activation of downstream signalling pathways is a mechanism of ALK inhibitor resistance in neuroblastoma

Mareike Bock, Berlin, Germany

23:50

PA10.3 New therapeutic strategies for neuroblastoma: Targeting Gal-3BP with a highly potent Antibody-Drug Conjugate

Gianluca Sala, Chieti, Italy

00:05

PA10.4 The astatine-labeled PARP inhibitor [211At]MM4 induces complete and durable responses in neuroblastoma patient derived xenograft (PDX) models

Minu Samanta, Philadelphia, USA

PA11 Core Regulatory Circuitries

23:20

PA11.1 Efficacious targeting of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy

Tao Liu, Kensington, Australia

23:35

PA11.2 SOX11 as guardian of epigenetic plasticity in neuroblastoma

Bieke Decaesteker, Ghent, Belgium

23:50

PA11.3 The neuroblastoma specific lincRNA NESPR controls noradrenergic cell identity and neuroblastoma cell survival

Eric James De Bony, Ghent, Belgium

PA12: Immune landscape of neuroblastoma

23:20

PA12.1 Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) Plus Cytokines for Patients with High-risk Neuroblastoma: Children’s Oncology Group Study ANBL0032

Alice Yu, San Diego, USA

23:35

PA12.2 A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma: An Update on Early Response and EFS

Wayne Furman, Memphis, USA

23:50

PA12.3 Haploidentical stem cell transplantation and subsequent immunotherapy with anti-GD2 antibody for patients with relapsed metastatic neuroblastoma

Tim Flaadt, Tuebingen, Germay

00:05

PA12.4 Discovery and Immunotherapeutic Targeting of Lineage-restricted Major Histocompatibility Complex (MHC) Antigens in Neuroblastoma

Mark Yarmarkovich, Philadelphia, USA

PA13: Hot and cold tumours

23:20

PA13.1 High Throughput Proteomic Profiling of the Cell Surfaceome Identifies PTK7 as a Novel Immunotherapeutic Candidate for Neuroblastoma

Kelly Goldsmith, Atlanta, USA

23:35

PA13.2 Particular poor treatment outcome of high-risk patients with low affinity FCGR2A/3A and IL-2-related high regulatory T cell levels during dinutuximab beta long-term infusion in two independent cohorts

Sascha Troschke-Meurer, Greifswald, Germany

23:50

PA13.3 Immune correlative markers in refractory or relapsed neuroblastoma patients treated with irinotecan/temozolomide/dinutuximab immunotherapy

Mitchell Diccianni, San Diego, USA

00:05

PA13.4 GD2-directed bispecific trifunctional antibody demonstrates therapeutic activity in a metastasized murine neuroblastoma model

Felix Zirngibl, Berlin, Germany

00:20

End of ANR2021